H.R.1733 - Senior Bill of Rights Act of 2003108th Congress (2003-2004)
|Sponsor:||Rep. Crowley, Joseph [D-NY-7] (Introduced 04/10/2003)|
|Committees:||House - Energy and Commerce; Ways and Means; Veterans' Affairs; House Administration|
|Latest Action:||House - 05/21/2003 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.1733 — 108th Congress (2003-2004)All Information (Except Text)
Senior Bill of Rights Act of 2003 - Amends title XVIII (Medicare) of the Social Security Act (SSA) to provide for a voluntary Medicare outpatient prescription medicine benefit program with a monthly premium of $25, a $100 annual deductible, 20 percent coinsurance, and an annual out-of-pocket spending limit of $2,000. Directs the Secretary of Health and Human Services to negotiate for maximum prices with medicine manufacturers.
Introduced in House (04/10/2003)
Establishes a Medicare Prescription Medicine Advisory Committee.
Amends SSA title XVIII part C (Medicare+Choice) to require Medicare+Choice organizations to make actuarially equivalent outpatient prescription medicines available under their plans. Requires Medigap policies also to cover such medicines. Provides for transitional assistance to low-income beneficiaries.
Prescription Drug Fairness for Seniors Act of 2003 - Requires each participating manufacturer to make covered outpatient drugs available at a price no greater than the manufacturer's average foreign price. Declares the sense of Congress that the cost disparity between identical prescription drugs sold in the United States, Canada, and Mexico should be reduced or eliminated.
Amends the Internal Revenue Code to disallow any deduction for any amount paid or incurred for a direct-to-consumer advertisement of a prescription drug.
Greater Access to Affordable Pharmaceuticals Act of 2003 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to: (1) abbreviated new generic drug applications, including forfeit to the next applicant by previous applicants who fail to market a drug within 90 days of approval or meet other specified requirements; (2) specified bioequivalence tests other than those for absorption rate and extent assessment; (3) requirements for citizen petitions regarding new drug applications; (4) actions for patent infringement; and (5) requirements for new drug applications, including mandatory patent information.
Preserving Access to Safe Affordable Canadian Medicines Act of 2003 - Amends FFDCA to prohibit prescription medication manufacturers from taking actions to discriminate against, or cause other persons to discriminate against, U.S. consumers regarding the purchase of prescription medications from Canadian pharmacies.
Prohibits the Commissioner of Food and Drugs from approving any new drug application that does not, before completion of the approval process, provide the Secretary a written statement specifying the total cost of research and development with respect to such drug.
Amends the Federal Election Campaign Act of 1971 to prohibit the chief executive officer of a pharmaceutical company from contributing to a political party or candidate.
Rescinds the February 2002 veterans medication copayment increase, and reinstates the $2 copayment.
Declares that all Social Security and Medicare funds shall be walled off into a lock box that may not be raided for new programs or tax cuts for the rich.